Members of "http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&mv1=5&mv2=1&mh1=0&mh2=0&mh3=0&mh4=0&ms=0&any=2012&num=140" BERENICE consortium about Chagas’ disease, led by Dr. Israel Molina, researcher of the Infectious Diseases group at Vall d’Hebron Institute of Research (VHIR), had their First General Assembly on the 26th June 2013 at Vall d’Hebron Universitary Hospital (HUVH). The main objective of the meeting was to discuss the progress of the program with its 8 European and Latin American partners. This project started on 1st September 2012 for a period of 5 years, and is currently in its 10th month of execution.  BERENICE is a European funded research project that aims to obtain a more effective drug against Chagas’ disease, with a better relation cost-benefit and especially that diminishes the side effects of the current treatments.The encapsulation of benznidazole using nanotechnology will generate a new drug delivery system. This new approach will allow a release of medication directly into the intracellular space, therefore increasing tissue drug concentration and avoiding side effects. A better toxic profile will be obtained because of the reduced amount of benznidazole that will be used in new treatments.